Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2169/internalmedicine.5288-20 http://scihub22266oqcxt.onion/10.2169/internalmedicine.5288-20 32999229!7725625!32999229     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intern+Med 2020 ; 59 (22): 2927-2930 Nephropedia Template TP {{tp|p=32999229|t=2020. Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course |pdf=|usr=}}{{32999229}} gab.com Text Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course JO: Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32999229 #FOAvip Tocilizumab (TCZ; Actemra/RoActemra) is an anti-interleukin (IL)-6 receptor antibody for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases and cytokine storms. The present case is a 63-year-old female well-controlled RA patient, who presented with a progressive cognitive impairment after 34 months of TCZ administration. Brain magnetic resonance imaging (MRI) showed leukencephalopathy with a lactic acid peak in magnetic resonance spectroscopy (MRS), a decreased blood flow in single photon emission computed tomography (SPECT), and a decreased accumulation in fluorodeoxyglucose positron emission tomography (FDG-PET). The discontinuation of TCZ improved her cognitive function and brain MRI findings at 3 months after drug cessation. The present case suggests that TCZ may sometimes cause leukoencephalopathy after long-term administration, and thus the early discontinuation of TCZ is recommended to achieve a good prognosis. Twit Text FOAVip Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course ????Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=32999229 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32999229 #FOAvip English Wikipedia <ref>{{Cite pmid|32999229}}</ref> Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course #MMPMID32999229 Sasaki R; Hishikawa N; Nomura E; Omote Y; Takemoto M; Yamashita T; Hatanaka N; Higashi Y; Abe K Intern Med 2020[Nov]; 59 (22): 2927-2930 PMID32999229show ga Tocilizumab (TCZ; Actemra/RoActemra) is an anti-interleukin (IL)-6 receptor antibody for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases and cytokine storms. The present case is a 63-year-old female well-controlled RA patient, who presented with a progressive cognitive impairment after 34 months of TCZ administration. Brain magnetic resonance imaging (MRI) showed leukencephalopathy with a lactic acid peak in magnetic resonance spectroscopy (MRS), a decreased blood flow in single photon emission computed tomography (SPECT), and a decreased accumulation in fluorodeoxyglucose positron emission tomography (FDG-PET). The discontinuation of TCZ improved her cognitive function and brain MRI findings at 3 months after drug cessation. The present case suggests that TCZ may sometimes cause leukoencephalopathy after long-term administration, and thus the early discontinuation of TCZ is recommended to achieve a good prognosis. |Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use[MESH] |Arthritis, Rheumatoid/blood/diagnosis/*drug therapy[MESH] |Cytokines/blood[MESH] |Female[MESH] |Humans[MESH] |Leukoencephalopathies/*chemically induced/diagnosis[MESH] |Magnetic Resonance Imaging/methods[MESH] |Middle Aged[MESH]Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Cou(epmc).pdf DeepDyve Pubget Overpricing